Y
Yi He
Researcher at AstraZeneca
Publications - 7
Citations - 275
Yi He is an academic researcher from AstraZeneca. The author has contributed to research in topics: Glembatumumab vedotin & Bevacizumab. The author has an hindex of 5, co-authored 7 publications receiving 183 citations.
Papers
More filters
Journal ArticleDOI
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
David A. Reardon,Annick Desjardins,James J. Vredenburgh,Donald M. O'Rourke,David Tran,Karen Fink,Louis B. Nabors,Gordon Li,Daniela A. Bota,Rimas V. Lukas,Lynn S. Ashby,J. Paul Duic,Maciej M. Mrugala,Scott Cruickshank,Laura Vitale,Yi He,Jennifer Green,Michael Yellin,Christopher D. Turner,Tibor Keler,Thomas A. Davis,John H. Sampson +21 more
TL;DR: The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glioblastoma, and supported the potential for targeted immunotherapy among patients with GBM.
Journal ArticleDOI
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
David A. Reardon,James M. Schuster,David Tran,Karen Fink,Louis B. Nabors,Gordon Li,Daniela A. Bota,Rimas V. Lukas,Annick Desjardins,Lynn S. Ashby,J. Paul Duic,Maciej M. Mrugala,Andrea Werner,Thomas Hawthorne,Yi He,Jennifer Green,Michael Yellin,Christopher D. Turner,Thomas A. Davis,John H. Sampson +19 more
TL;DR: The investigational vaccine rindopepimut consists of an EGFRvIII constitutively active EGFR deletion driver mutation and a booster adjuvant that acts as a ‘spatially aggregating force’ to reprogram the EGFR into an ‘exciting’ substance.
Journal ArticleDOI
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Patrick A. Ott,Anna C. Pavlick,Douglas B. Johnson,Lowell L. Hart,Jeffrey R. Infante,Jason J. Luke,Jose Lutzky,Neal Evan Rothschild,Lynn E. Spitler,C. Lance Cowey,Aaron R. Alizadeh,April K.S. Salama,Yi He,Thomas Hawthorne,Rebecca G. Bagley,Joshua Zhang,Christopher D. Turner,Omid Hamid +17 more
TL;DR: The objective of the current study was to investigate further the antitumor activity of glembatumumab vedotin at the recommended phase 2 dose in heavily pretreated patients with melanoma.
Journal ArticleDOI
IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
David A. Reardon,Annick Desjardins,James M. Schuster,David Tran,Karen Fink,Louis B. Nabors,Gordon Li,Daniela A. Bota,Rimas V. Lukas,Lynn S. Ashby,J. Paul Duic,Maciej M. Mrugala,Andrea Werner,Laura Vitale,Yi He,Jennifer Green,Michael J. Yellin,Christopher D. Turner,Thomas A. Davis,John Sampson +19 more
TL;DR: Rindopepimut induces potent EGFRvIII-specific immune response and tumor regression, and appears to significantly prolong survival when administered with BV, in pts with relapsed GB.
Journal ArticleDOI
107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma
David A. Reardon,James M. Schuster,David Tran,Karen Fink,Louis B. Nabors,Gordon Li,Daniela A. Bota,Rimas V. Lukas,Annick Desjardins,Lynn S. Ashby,J. Paul Duic,Maciej M. Mrugala,Andrea Werner,Thomas Hawthorne,Yi He,Jennifer Green,Michael Yellin,Christopher D. Turner,Thomas A. Davis,John Sampson +19 more
TL;DR: These near-final data show that rindopepimut induces potent EGFRvIII-specific immune response and tumor regression, and appears to significantly prolong survival when administered with BV in patients with relapsed GB.